Jan. 27 at 6:49 PM
$CNTX I am paraphrasing from their Nov. update. #3 IND is intriguing to me (recall last time their other IND was approved)
1. CTIM-76: CLDN6 x CD3 bispecific TCE in Phase 1 dose escalation for patients with ovarian, endometrial, or testicular cancer. The CTIM-76 clinical trial (NCT06515613) can be found on https://clinicaltrials.gov/.
• Context anticipates providing updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026.
2. CT-95: MSLN x CD3 bispecific TCE in Phase 1 dose escalation for patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancer.
The CT-95 clinical trial (NCT06756035).
• Anticipates providing initial Phase 1a data in the middle of 2026.
3. CT-202: Nectin-4 x CD3 bispecific TCE in preclinical development for patients with bladder, non-small cell lung, colorectal, breast, and head and neck cancer.
• Expects to complete regulatory filings to initiation of a first-in-human trial in the 2ndQtr of 2026.
